Additional file 1 of Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial

Institutions

Publication Details

Journal
Figshare
Published
2025-01-01
DOI
https://doi.org/10.6084/m9.figshare.29035915.v1
Primary Topic
Bone Metabolism and Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Additional file 1 of Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial

Figshare
Bone Metabolism and Diseases
article

Additional file 1 of Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial

article en

Abstract

No abstract available for this paper.
Figshare
Bellvitge University Hospital (ES), Institut d'Investigació Biomédica de Bellvitge (ES), Spanish National Cancer Research Centre (ES), Institut Català d'Oncologia (ES), Osakidetza (ES), Clinica Universidad de Navarra (ES), Universitat de Barcelona (ES)
Good health and well-being
Openalex Percentile: Top 61%
Bone Metabolism and Diseases
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Additional file 1 of Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial · Figshare (2025) | TGRS Research Map | TGRS